Ozempic, a popular diabetes medication, is at the center of one of the largest pharmaceutical lawsuits in recent years. Over 1,800 cases have been filed, with many more expected to be added, as patients claim that Novo Nordisk, the manufacturer, failed to adequately warn them about serious side effects.
The drug, which was originally approved for type 2 diabetes treatment, has become increasingly popular for weight loss due to its appetite-suppressing properties. However, patients have reported a range of severe health problems, including stomach paralysis, intestinal blockages, and persistent vomiting, as well as gallbladder complications and vision loss.
Research studies have linked the use of GLP-1 receptor agonists like Ozempic to an increased risk of developing these conditions. Despite this evidence, Novo Nordisk denies that the full scope of potential harm was communicated to patients.
The lawsuits are now in the discovery phase, with both sides gathering documents and preparing expert witnesses for bellwether trials expected to begin in early 2026. If juries side with plaintiffs, Novo Nordisk may be pushed toward a global settlement covering all pending cases.
Analysts estimate that the total liability could reach $2 billion or more, making it one of the costliest drug safety disputes in history. As the litigation unfolds, it is clear that the gap between how drugs are approved and how they are later used remains a pressing concern for regulators and manufacturers alike.
Source: https://www.financialexpress.com/business/healthcare-ozempic-faces-2-billion-lawsuits-as-patients-report-stomach-paralysis-vision-loss-explainer-3950636